Related Experiment Video
Updated: Jun 21, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management.
David M Thomas1, Brian O'Sullivan, Alessandro Gronchi
1Peter MacCallum Cancer Centre, St Andrew's Place East Melbourne Victoria, Australia. david.thomas@petermac.org
Expert Review of Anticancer Therapy
|August 13, 2009
Summary
Retroperitoneal soft-tissue sarcomas are challenging cancers requiring multidisciplinary care. Treatment involves aggressive surgery, with radiotherapy and chemotherapy playing roles in specific settings and advanced disease.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Retroperitoneal soft-tissue sarcomas are rare, heterogeneous cancers.
- They present diagnostic and therapeutic challenges due to size and location.
- Common adult subtypes include liposarcomas and leiomyosarcomas; pediatric subtypes differ.
Purpose of the Study:
- To provide an overview of retroperitoneal soft-tissue sarcomas.
- To discuss current and emerging treatment strategies.
- To highlight the importance of multidisciplinary care.
Main Methods:
- Review of current literature on retroperitoneal soft-tissue sarcomas.
- Discussion of surgical, radiotherapeutic, and chemotherapeutic approaches.
- Exploration of novel targeted therapies.
Main Results:
- Surgery is critical for local control and palliation.
- Radiotherapy aids in relapse reduction, with need for prospective trials.
- Chemotherapy has limited adjuvant role but increasing importance in advanced disease.
Conclusions:
- Multidisciplinary care is essential for managing these complex tumors.
- Novel targeted agents show promise for specific subtypes.
- Further research, including prospective trials, is needed for optimal treatment strategies.
